$25.91
Insights on Semler Scientific Inc
Revenue is down for the last 3 quarters, 18.60M → 15.05M (in $), with an average decrease of 10.0% per quarter
Netprofit is down for the last 3 quarters, 5.87M → 4.22M (in $), with an average decrease of 14.8% per quarter
In the last 1 year, Boston Scientific Corp. has given 42.7% return, outperforming this stock by 41.4%
0.5%
Downside
Day's Volatility :3.07%
Upside
2.58%
11.93%
Downside
52 Weeks Volatility :57.25%
Upside
51.46%
Period | Semler Scientific Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -40.13% | 1.1% | 0.0% |
6 Months | -11.97% | 12.5% | 0.0% |
1 Year | 6.99% | 6.9% | 2.2% |
3 Years | -79.04% | 14.3% | -23.0% |
Market Capitalization | 190.5M |
Book Value | $10.43 |
Earnings Per Share (EPS) | 2.63 |
PE Ratio | 10.3 |
PEG Ratio | 0.0 |
Wall Street Target Price | 65.0 |
Profit Margin | 30.19% |
Operating Margin TTM | 17.65% |
Return On Assets TTM | 20.42% |
Return On Equity TTM | 32.29% |
Revenue TTM | 68.2M |
Revenue Per Share TTM | 10.13 |
Quarterly Revenue Growth YOY | 9.1% |
Gross Profit TTM | 52.4M |
EBITDA | 23.3M |
Diluted Eps TTM | 2.63 |
Quarterly Earnings Growth YOY | 0.32 |
EPS Estimate Current Year | 3.4 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.57 |
EPS Estimate Next Quarter | 1.18 |
What analysts predicted
Upside of 150.87%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 21.5M | ↑ 72.59% |
Net Income | 5.0M | ↓ 432.05% |
Net Profit Margin | 23.33% | ↑ 35.46% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 32.8M | ↑ 52.47% |
Net Income | 15.1M | ↑ 200.84% |
Net Profit Margin | 46.03% | ↑ 22.7% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 38.6M | ↑ 17.81% |
Net Income | 14.0M | ↓ 7.14% |
Net Profit Margin | 36.28% | ↓ 9.75% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 53.0M | ↑ 37.36% |
Net Income | 17.2M | ↑ 22.95% |
Net Profit Margin | 32.48% | ↓ 3.8% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 56.7M | ↑ 6.9% |
Net Income | 14.3M | ↓ 16.82% |
Net Profit Margin | 25.27% | ↓ 7.21% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 68.2M | ↑ 20.28% |
Net Income | 20.6M | ↑ 43.69% |
Net Profit Margin | 30.19% | ↑ 4.92% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 14.0M | ↓ 5.27% |
Net Income | 3.7M | ↓ 9.79% |
Net Profit Margin | 26.16% | ↓ 1.32% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 13.8M | ↓ 1.8% |
Net Income | 3.2M | ↓ 12.49% |
Net Profit Margin | 23.31% | ↓ 2.85% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.2M | ↑ 31.98% |
Net Income | 5.0M | ↑ 54.51% |
Net Profit Margin | 27.29% | ↑ 3.98% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.6M | ↑ 2.19% |
Net Income | 5.9M | ↑ 18.31% |
Net Profit Margin | 31.6% | ↑ 4.31% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.3M | ↓ 12.3% |
Net Income | 5.5M | ↓ 6.21% |
Net Profit Margin | 33.8% | ↑ 2.2% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 15.1M | ↓ 7.72% |
Net Income | 4.2M | ↓ 23.45% |
Net Profit Margin | 28.04% | ↓ 5.76% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 7.7M | ↑ 82.14% |
Total Liabilities | 3.5M | ↓ 48.35% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 18.3M | ↑ 136.91% |
Total Liabilities | 5.2M | ↑ 48.0% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 34.6M | ↑ 89.42% |
Total Liabilities | 4.8M | ↓ 7.06% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 50.7M | ↑ 46.29% |
Total Liabilities | 5.1M | ↑ 5.76% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 62.7M | ↑ 23.72% |
Total Liabilities | 7.0M | ↑ 36.92% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 78.1M | ↑ 24.52% |
Total Liabilities | 6.3M | ↓ 10.65% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 60.9M | ↑ 5.7% |
Total Liabilities | 8.6M | ↑ 22.98% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 62.7M | ↑ 2.91% |
Total Liabilities | 7.0M | ↓ 18.09% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 70.3M | ↑ 12.07% |
Total Liabilities | 9.1M | ↑ 29.06% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 75.5M | ↑ 7.41% |
Total Liabilities | 10.2M | ↑ 12.62% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 79.4M | ↑ 5.28% |
Total Liabilities | 8.7M | ↓ 14.99% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 78.1M | ↓ 1.73% |
Total Liabilities | 6.3M | ↓ 27.68% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.7M | ↑ 656.36% |
Investing Cash Flow | -843.0K | ↓ 12.91% |
Financing Cash Flow | -2.0M | ↓ 271.49% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 12.7M | ↑ 170.98% |
Investing Cash Flow | -1.7M | ↑ 101.42% |
Financing Cash Flow | -6.6M | ↑ 224.27% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 15.4M | ↑ 21.13% |
Investing Cash Flow | -1.3M | ↓ 22.91% |
Financing Cash Flow | 230.0K | ↓ 103.5% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 16.1M | ↑ 4.14% |
Investing Cash Flow | -825.0K | ↓ 36.97% |
Financing Cash Flow | 13.0K | ↓ 94.35% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 17.5M | ↑ 8.76% |
Investing Cash Flow | -26.8M | ↑ 3152.73% |
Financing Cash Flow | -4.9M | ↓ 38076.92% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.0M | ↑ 28.75% |
Investing Cash Flow | -491.0K | ↓ 72.43% |
Financing Cash Flow | -2.0M | ↓ 28.8% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.7M | ↓ 78.68% |
Investing Cash Flow | -24.3M | ↑ 4850.51% |
Financing Cash Flow | 75.0K | ↓ 103.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 861.0K | ↓ 49.65% |
Investing Cash Flow | -18.4M | ↓ 24.2% |
Financing Cash Flow | -146.0K | ↓ 294.67% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 11.2M | ↑ 1200.35% |
Investing Cash Flow | 25.0M | ↓ 235.52% |
Financing Cash Flow | -2.0M | ↑ 1252.74% |
Sell
Neutral
Buy
Semler Scientific Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Semler Scientific Inc | -9.21% | -11.97% | 6.99% | -79.04% | -79.04% |
Stryker Corporation | -3.86% | 30.27% | 12.73% | 26.98% | 78.91% |
Dexcom, Inc. | -1.59% | 63.45% | 11.22% | 31.69% | 366.88% |
Boston Scientific Corp. | 7.32% | 46.46% | 42.68% | 72.49% | 95.05% |
Abbott Laboratories | -2.84% | 13.74% | -1.71% | -12.8% | 36.06% |
Medtronic Plc | -3.97% | 14.22% | -10.66% | -38.23% | -7.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Semler Scientific Inc | 10.3 | 10.3 | 0.0 | 3.4 | 0.32 | 0.2 | NA | 10.43 |
Stryker Corporation | 40.64 | 40.64 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Dexcom, Inc. | 102.89 | 102.89 | 2.53 | 1.76 | 0.26 | 0.06 | NA | 5.37 |
Boston Scientific Corp. | 64.48 | 64.48 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Abbott Laboratories | 33.52 | 33.52 | 5.99 | 4.31 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.81 | 25.81 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Semler Scientific Inc | Buy | $190.5M | -79.04% | 10.3 | 30.19% |
Stryker Corporation | Buy | $127.4B | 78.91% | 40.64 | 15.44% |
Dexcom, Inc. | Buy | $54.6B | 366.88% | 102.89 | 14.95% |
Boston Scientific Corp. | Buy | $101.4B | 95.05% | 64.48 | 11.18% |
Abbott Laboratories | Buy | $186.7B | 36.06% | 33.52 | 13.96% |
Medtronic Plc | Buy | $107.9B | -7.98% | 25.81 | 13.0% |
HPM Partners LLC
Vanguard Group Inc
BlackRock Inc
LSV Asset Management
CI Private Wealth LLC
D. E. Shaw & Co LP
semler scientific, inc. is an emerging medical risk-assessment company whose diagnostic and testing products and services help to guide patient care and close the gap between cost of care and compensation for care. semler closed the initial public offering of its common stock on february 26, 2014 and its common stock is now listed under the ticker symbol "smlr." additional information about semler can be found at www.semlerscientific.com.
Organization | Semler Scientific Inc |
Employees | 92 |
CEO | Ms. Renae Cormier |
Industry | Medical Specialties |